COMMUNIQUÉS West-GlobeNewswire

Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

27/09/2024 - 00:44

MIAMI, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor [...]

Cassava Sciences Resolves SEC Investigation

27/09/2024 - 00:15

AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced that it has reached a [...]

Humacyte to Host Virtual KOL Event to Discuss Case Studies on the Use of Acellular Tissue Engineered Vessel (ATEV™) in Vascular Trauma Treatment on September 30, 2024

26/09/2024 - 23:26

DURHAM, N.C., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today [...]

Streamline Health® Announces 1-For-15 Reverse Stock Split

26/09/2024 - 23:18

ATLANTA, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (“Streamline” or the “Company”) (NASDAQ: STRM), a leading provider of solutions that enable healthcare providers to improve financial [...]

Qualigen Therapeutics, Inc. Announces management changes.

26/09/2024 - 23:10

CARLSBAD, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced on September 23, 2024, Mr. Michael Poirier, notified the board of directors of the Company (the [...]

Medicenna Announces Results of Annual Meeting of Shareholders

26/09/2024 - 23:00

TORONTO and HOUSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of [...]

Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update

26/09/2024 - 22:30

-Positive 90-day and 180-day Interim Clinical Trial Data for the First Oculopharyngeal Muscular Dystrophy (OPMD) Subject Dosed with the Low-Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in April [...]

Cue Biopharma Announces Proposed Public Offering

26/09/2024 - 22:27

BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease- [...]

Better Choice Company to Present at the 2024 ThinkEquity Conference and Provides Detail on Sales in China and the Acquisition of SRx Health

26/09/2024 - 22:10

Sustained Sales Momentum in China in Q3 Following 37% Sequential Growth in Q2 Acquisition of SRx Health Remains On-Track TAMPA, Fla., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Better Choice Company (NYSE: BTTR) (“Better Choice [...]

Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024

26/09/2024 - 22:05

TARRYTOWN, N.Y., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its third quarter 2024 financial and operating results on Thursday, October 31, [...]

Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly

26/09/2024 - 22:05

SAN DIEGO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for paltusotine [...]

Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET

26/09/2024 - 22:05

New Istaroxime Phase 2b clinical results to be presented by Windtree and top cardiology expert Review of cardiogenic shock and other programs, including Windtree’s strategy and planned near-term milestones WARRINGTON, [...]

QIAGEN receives European IVDR certification for QIAstat-Dx syndromic testing instruments and assays

26/09/2024 - 22:05

Product line earns CE-marking under new EU IVDR framework – including QIAstat-Dx Analyzer, QIAstat-Dx Rise and panels for detection of gastrointestinal and respiratory infections // Certification confirms that QIAGEN’s [...]

NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M

26/09/2024 - 22:03

TORONTO and HAIFA, Israel, Sept. 26, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “ Company ” or “ NurExone ”), a biopharmaceutical company developing exosome-based [...]

Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up

26/09/2024 - 22:01

Company to host conference call today at 4:30 p.m. ET SAN DIEGO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced a voluntary pause of enrollment in the Phase 3 HARMONY Study [...]

Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30

26/09/2024 - 22:01

CAMBRIDGE, Mass., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (“Seres” or the “Company”), a leading live biotherapeutics company, today announced that its stockholders voted to approve [...]

Clover Health Appoints Seasoned Healthcare Executive as Chief Operating Officer for Medicare Advantage Operations

26/09/2024 - 22:00

New Jersey Native Joseph Brand to Lead Operational Efficiency and Innovation in MA Operations, Enhancing Care for Physicians and Patients FRANKLIN, Tenn., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, [...]

Grant of Restricted Stock Units and Warrants to Employees in Genmab

26/09/2024 - 21:17

Company Announcement COPENHAGEN, Denmark; September 26, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 23,954 restricted stock units and 13,915 warrants to employees of the Company and [...]

FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials

26/09/2024 - 20:00

REDWOOD CITY, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent [...]